AGC Biologics has started NN4101 bispecific antibody development and GMP production with Novelty Nobility. The project moves Copenhagen cell-line and MCB work to GMP manufacturing in Chiba from May 2026. The therapy targets retinal neovascular disease. AGC global cGMP network enables technology transfer.
Insights / Pharma
PharmaAGC Biologics starts NN4101 bispecific antibody development and GMP production
AGC Biologics has started development and GMP production of NN4101, a bispecific antibody with Novelty Nobility, moving Copenhagen cell-line and MCB work to GMP manufacturing in Chiba from May 2026, targeting retinal neovascular disease.
